INTRODUCTION
Pharmaceutical expenditure has been rising during the past decade with growth rates up to 13% per annum, which is typically greater than other components of health care [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Overall, expenditure on pharmaceuticals has further enhance their prescribing efficiency as they struggle to meet patient demands, especially with pharmaceutical budgets now being cut in some countries [12, 35, 36] . This has been recognised by High Level Pharmaceutical Forums and the European Commission, both emphasising the need for increased use of generics, with competition enhancing the potential for lower prices for generics in order that more patients can be treated within target budgets [11, 40, [71] [72] [73] . In addition, potentially liberating monies to fund new innovative drugs [6] [7] [8] [9] [10] [11] 40, 71, 72] . However, this philosophy has not always been followed by individual companies, some of whom try and manipulate the market to maintain sales of their originator products for as long as possible [6, 52, 54, 74] . The World Health Organization (WHO) also endorses the use of generics when discussing the rational use of medicines as well as potential strategies to release resources to help maximise health gain with available budgets [17, 40, 63, 70, 75] . This is different to the instigation of outpatient tendering for pharmaceuticals to help reduce costs, which may also include generics [13] . The various initiatives can be divided into supply-side reforms and demand-side reforms. Supply-side reforms include measures to lower the price of generics, accelerate their marketing authorisation, reference pricing for the molecule (Anatomical Therapeutic Classification -ATC -Level 5 [76] ), the class (ATC Level 4) or the therapeutic area (ATC Level 3), as well as compulsory price cuts when target budgets are being exceeded [1] [2] [3] [4] [5] [6] [7] [8] 10, 11, 14, 15, [31] [32] [33] [34] [35] 37, 38, [40] [41] [42] 44, 52, 77, 78] . Demand-side measures include those to enhance the prescribing, requesting and dispensing of generics versus originators, as well as enhance the prescribing of generics in a class or related class versus still patented products where all drugs in the class are seen as essentially similar for all or nearly all patients [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] 15, [31] [32] [33] [34] [35] [36] [37] [38] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] 63] . This includes the promotion of lower cost medicines where generics are available in a class, e.g. Belgium and Germany [11, 31, 40, 53, 66] . Patient care should not be compromised with increased use of generics versus originators apart from a small number of well known examples [3, 4, [6] [7] [8] 10, 15, 37, 38, 41, 79, 80] . These include cyclosporine, lithium, certain long acting calcium channel blockers as well as some morphine preparations [31, 41, 79, 80] . This is because in Europe generic medicines have to demonstrate the same qualitative and quantitative composition and the same pharmaceutical formulation and bioavailability as the originator medicine to receive market total health care expenditure in 2009, ranging from 7.3% in Denmark to 32.6% in Hungary [12, 16, 17] . This is set to continue unless addressed, driven by well recognised factors including strict clinical targets, changing demographics with ageing populations, the continued launch of new premium priced drugs and rising patient expectations [1] [2] [3] [4] [5] 7, 8, 12, 15, 18] . New cancer drugs are a particular concern with cancer rates rising, cancer now seen as a chronic disease through advances in treatments, the acquisition costs of cancer drugs typically higher than average drug costs, and new cancer drugs currently a significant proportion of new drugs in development, estimated currently at over 350, with some new cancer drugs being launched at approximately US$10,000 per month [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . As a result, health authorities and health insurance companies across Europe have instigated multiple reforms to slow down this growth in expenditure, or even reverse it, to maintain the European ideals of equitable and comprehensive health care [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] 15, . The alternative is no or reduced funding for new innovative premium priced drugs as authorities struggle to stay within agreed budgets during this current financial situation, and greater acknowledgement of opportunity costs, which is already happening [6, 9, 12, 35, [55] [56] [57] . This is not in the best interest of all major stakeholder groups. The reforms and initiatives include measures to enhance prescribing efficiency for both new and existing drugs. Initiatives for new drugs include the development of new models to help optimise their use, which centre on three pillars. The three pillars include horizon scanning and budgeting pre-launch, critical drug evaluation peri-launch including possible risk-sharing arrangements, as well as monitoring of prescribing against agreed guidance post launch and, where possible, patient registries to assess the effectiveness and safety of new drugs in routine care [18, 19, [58] [59] [60] [61] [62] [63] [64] [65] . Considerable effort has been directed towards enhancing the prescribing efficiency of existing drugs, based on generics [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] 15, 33, 40, 66] . This especially with global sales of pharmaceutical products likely to lose their patents between 2008 and 2013 estimated at US$50-100bn (€35-70), and US$255bn between 2011 and 2016, out of total pharmaceutical sales of US$820bn in 2009 (€579bn) including US$700bn from OECD countries [6] [7] [8] [9] [10] 15, [67] [68] [69] , and generic substitution estimated to reduce costs to patients by an average of 60% in middle income countries alone [17, 70] . As a result, present considerable opportunities for European countries to learn from each other to [6, 8, 10, 15, 40, 81] . The predefined acceptance limits for bioequivalence for different batches of generics ensure that plasma concentrations vary only by 3-4% on average from those of the originator, i.e. the same for different batches of the originator, which is seen as clinically irrelevant in the vast majority of situations [81, 82] . As a result, health authority and health insurance company personnel typically assume that if two medicines have the same bioavailability they should have a similar therapeutic effect. This is typically the case even when the generic is a different salt to the originator with initially different indications when first approved by the European Medicines Agency (EMA). This happened with generic clopidogrel despite the efforts of the originator company to persuade physicians to continue prescribing Plavix® [52, 82, 83] . This belief is strengthened by the continual monitoring of the quality of generics by EMA and regulatory authorities in member states, leading for instance to the withdrawal of some versions of generic clopidogrel when there were concerns with the manufacturing process [52, 82] . This is illustrated by two recent literature reviews comparing the outcomes between generic and originator drugs for the treatment of different disease areas [84, 85] , which again failed to show any superiority of the originator [82] . The first review, which was concerned with medicines for the management of epilepsy, found no evidence of an association between loss of seizure control and treatment with a generic drug versus the originator with at least three anti-epileptic drugs, one of which was phenytoin [84] . Subsequent studies have shown that patients with epilepsy can be successfully switched between different generic versions of the same molecule [86] . The second review concerned various treatments for cardiovascular disease. This again failed to demonstrate any superiority in outcomes for originators compared with generic drugs of the same molecule [85] . This included drugs with a narrow therapeutic index such as propafenone and warfarin [85] . Recent published studies have also shown that generic and originator atorvastatin were equally effective in correcting the lipid profile and reducing the coronary risk in patients with hyperlipidemia and increased risk, and both were equally well tolerated [87] . Patient care should also not be compromised with increased use of generics versus existing patented products in high volume classes such as the proton pump inhibitors (PPIs), HMG CoA reductase inhibitors (statins) and renin-angiotensin system inhibitor drugs Essential to increase the use of generics in Europe to maintain comprehensive health care?
price. Secondly, a review of potential methods to enhance the prescribing and dispensing of generics versus originators. Thirdly, a review of potential methods to enhance the utilisation of generics versus patented products in a class or related classes. Fourth, combining supply-and demand-side measures in selected case histories to give future guidance.
Measures to obtain low prices for generics
European countries typically have different approaches to the pricing of generics, with member States free to develop their own national policies for the pricing and reimbursement of drugs [11] . However, they can be categorised into [1] [2] [3] [4] 6, 8, 10, 36, 37, [40] [41] [42] [43] [44] 46, 47, 76, [101] [102] [103] : -Prescriptive pricing policies (price regulated systems): this includes mandated prices for generics such as the "stepped price" model in Norway with a maximum 85% reduction versus pre-patent loss prices for high volume generics, and France where initially generics have to be priced at least 55% below pre-patent loss prices to be reimbursed. However, there are concerns depending on the level of the prescriptive price reductions that generic manufacturers will subsequently undertake appreciable discounting in the distribution chain to enhance the possibility of their generic being preferentially dispensed. As a result, reducing competition whilst also reducing potential savings to health care systems, especially where the price of some generics vary up to 36 fold across countries depending on the molecule and country, potentially making some policies unsustainable in the long term. -Market forces: where there is free pricing. This is typically combined with measures to enhance the prescribing of generics versus originators including high INN (International Non-proprietary Name) prescribing (voluntary or compulsory), compulsory substitution or financial incentives including additional co-payments for a more expensive product than the referenced price molecule (ATC Level 5). -Mixed approach (combination of the two): this combines both approaches, e.g. in Finland the first generic must be priced at least 40% below pre-patent loss originator prices to be reimbursed, with subsequent generics priced lower to be reimbursed along with market force measures encouraging the prescribing and dispensing of the least costly generic. In Austria, the first generic must be priced between ARBs for the management of hypertension or heart failure when used at optimal doses, although typically higher doses are needed for heart failure. In addition, published studies have shown that patients can be successfully switched between ARBs.
OBJECTIVE
The objective of this paper is to review the influence of the plethora of measures and initiatives introduced across Europe in recent years to enhance the prescribing and dispensing of generics at low prices. In view of this, improve prescribing efficiency in ambulatory care especially for drugs in high volume classes. In this case, prescribing efficiency is defined as drug volumes increasing at a faster rate than expenditure where the drugs in each class or related class are seen as essentially similar in all or nearly all patients. As a result, provide guidance to health authorities and health insurance companies across Europe as they strive to instigate additional measures to further enhance their prescribing efficiency to meet their goals.
METHODOLOGY
This is a narrative review of papers on the influence of generics on increasing prescribing efficiency. The papers will principally be taken from the extensive number of publications that the co-authors have either been involved with or are known to them. Case histories will also be included to further illustrate the influence of multiple measures. These will again be based on publications or internal documents known to the co-authors. We did not undertake a systematic review of published papers concerning generics, as this has already been performed by the coauthors and others. In addition, we did not critique the quality of the papers using established methodologies as a number of the papers quoted are reviews rather than primary research. However, we believe our approach is valid given the extensive experience and publications of the co-authors from across Europe with instigating measures and initiatives to lower the prices of generics as well as increase their utilisation versus originators and patented products in a class.
RESULTS
These will be divided into four components. Firstly, a review of different approaches to the pricing of generics from across Europe combined with selected case histories which illustrate potential ways to achieve low 48% below pre-patent loss originator prices to be reimbursed, the second generic 15% below this, and the third generic 10% below the second. This results in 60% below pre-patent loss prices for reimbursement (also setting the reimbursed price also for the originator). Successive generics must be priced at least 10 cents per pack lower than the previous generic to be reimbursed, with mar- Croatia (mixed approach) [9, [32] [33] [34] • First generic must be priced no higher than 70% of the average prices in three countries in order (Italy, France and Slovenia); alternatively Spain or Czech Republic • Subsequent generics must be priced up to 90% of the last bioequivalent product to be reimbursed with market forces including higher co-payments for more expensive generics helping to lower prices • Alongside this instigation of a new reference pricing system for existing drugs (ATC Levels 3 and 4) based on the lowest price of products with a market share of at least 5% by expenditure during the preceding 12 months, with patients paying the price difference for a more expensive product. • The first generic launched must be priced no higher than 30% below the originator, the second generic at least 10% lower than the first generic on a pack basis and the third generic 10% lower than the second to be reimbursed. Once there are more than 3 manufacturers for the molecule, a maximum list price for the originator at 60% above the cheapest generic Netherlands (mixed approach with increasingly market forces) [104] [105] [106] [107] [108] • In 2004, a covenant was instigated whereby generics should be priced no higher than 40% below the originator for reimbursement, with additional agreements after this to further lower prices • Preference pricing policy instigated in 2008 whereby only the cheapest generics would be reimbursed, with patients covering the costs for a non-preferred drug. Tenders were conducted for high volume generics to achieve low prices. This resulted in:
• appreciable price reductions of between 76% to 93% for the 10 largest generics by volume, leading to estimated savings of €348mn/year • the scheme being extended in 2009 as more generics became available resulting in pharmaceutical expenditure stabilizing in the Netherlands in recent years • both generic omeprazole and generic simvastatin in 2010 at just 2% of originator pre-patent loss prices (expenditure/DDD) However, there are concerns regarding the sustainability of pharmacies and the generic industry in the Netherlands as a result of the preference pricing policy Republic Srpska (mixed approach) [42] • -guaranteed the same absolute margin for both generic and originator medicines;
Essential to increase the use of generics in Europe to maintain comprehensive health care?

Measures to enhance the utilisation of generics versus originators
ket forces helping to drive prices down through IT systems and physician education to encourage the prescribing of the cheapest branded generic. Perhaps not surprising, the utilisation of generics versus originators is greater in countries where there is free pricing, with market forces used to drive down prices [39] . As a result, countries such as Slovenia are looking to introduce compulsory generic substitution along with reference pricing for therapeutic drug groups (cluster of drugs for the same therapeutic indication) to further lower prices, including generics, to contain costs. A number of case histories illustrating the influence of the various measures are contained in Table I . The case histories particularly in Lithuania and the Republic Srpska demonstrate that European countries with small populations can introduce multiple reforms including those to obtain low prices for generics [36, 42] . As a result, dispel myths that countries with smaller populations have difficulties negotiating with manufacturers and obtaining low prices for drugs [111] . Sweden (market forces) [3, 4, 6, 8, 15, 109, 110] Compulsory generic substitution was introduced in 2002 unless:
• the prescriber indicates that the drug should not be substituted on medical grounds • substitution may be restricted for reasons such as differences in taste for oral solutions or divided tablets • the patient is willing to pay the price difference for a more expensive branded generic originator In practice, substitution almost always happened helped by an increasing focus on drug costs within the regions (counties in Sweden) following devolution of drug budgets and physician acceptance of this reform. As a result:
• generic prices fell on average of 40% by the end of 2005 compared with 2002, with prices for high-volume drugs falling further -reaching 4 to 13% of originator pre-patent loss prices by 2009, helped a comprehensive technical support system enabling pharmacies to continually stock the cheapest product with prices reviewed at least twice a month by the reimbursement agency (TLV), facilitated by one national pharmacy chain -Apoteket AB -owned by and reporting directly to the government (currently TLV reviews the prices of generics once a month whilst the availability of generics is typically undertaken daily). The TLV estimated overall savings of €700 million (>6. 97 there are substitutable generic medicines available. In return, they received €1/package extra when dispensing drugs subject to generic competition • there are regular monthly auctions for generics, with the manufacturer with the lowest price wining the auction However, they must be able to supply the whole market for the entire period. This typically translates into 70% of the total sales during the period (almost 80% when the crossed prescriptions are excluded) when the washout period and out-of-stock situations are factored in This should lead to further falls in the prices of generics UK (market forces) [6, 8, 10, 15, 31, 33, 37, 38] • Introduction of the 'M' and 'W' (Manufacturer and Wholesaler) scheme in the UK in 2005 resulted in increasing transparency in the pricing of generics, as well as discounts and rebates offered by manufacturers to community pharmacists to preferentially dispense their generic • As a result, there was:
• an average 32.4% reduction in the prices of generics within the first year of introduction, resulting in a 2% reduction in overall pharmaceutical expenditure the year following its introduction. Prior to this, some generic manufacturers were offering discounts of up to 80% or more to community pharmacists to preferentially dispense their particular generic • reimbursed prices (tariff price) and expenditure/DDD for generic simvastatin 2% to 3 % of pre-patent loss originator prices Consequently, there is typically active monitoring of Drug Tariff prices by Pharmaceutical Advisers to enhance potential savings, as well as active monitoring of drug patent expiry dates to identify potential opportunities for switching drugs within a class (ATC Level 4) just before or just after generic availability [15] . The early analysis of the pilot P4P programme (Contrat d'Amélioration des Pratiques Individuelles -CAPI) also indicates a positive influence on physician behaviour; consequently, it has now been extended to all GPs in France [63] . In Portugal, the current target goal is to reduce NHS expenditure in 2012 by over 10% versus 2011 levels, and by a further 20% in 2013, achieved by introducing a range of supply-and demand-side measures. These include for pharmaceuticals: -Supply-side measures:
-pricing of generics -the first generic must be lower than 50% than the prepatent originator price to be reimbursed. By the time the fifth generic is available, its price must be 5% lower than the latest generic submitted for reimbursement; -instigation of a reference price system based on the 5 cheapest molecules (ATC Level 5), with patients covering the additional cost themselves for a more expensive molecule; -removing/reducing some of the current legal/administrative barriers to the entry of generics to hasten their introduction in Portugal. -Demand-side measures:
-generic advertising campaigns to all key stakeholder groups including physicians and patients ( Figure 1) ; -increasing IT support including electronic medical prescribing as well as other measures to enhance the rational use of medicines. These include alerts/pop-ups on the cheapest medicinal products available to treat the condition. They also include IT tools to monitor GP prescribing; -therapeutic guidelines (electronic and hard copy); -information given to the patient in the prescription about the amount that could be saved if the doctor would have chosen the cheapest medicine for the condition; -increasing patient co-payments by reducing NHS contributions of high volume ambulatory care drugs, e.g.: i)ulcer therapies decreased from 69 to 37%; ii) anti-inflammatory therapies decreased from 69 to 37%; iii) anti-depressants decreased from 95 to 37%. As a result, the generic market in Portugal expanded by16% January to October 2011, with costs decreasing by 12%. This favourably impacted on the total market where both volumes and costs are now decreasing. Other examples to increase the prescribing and dispensing of generics versus originators, some of which are described in Table I,  include: -Lithuania, where all reimbursed prescriptions should be written by INN name except biological products, unless the physician receives prior approval from the Hospital or Polyclinic Therapeutic Committee [36] ; -Sweden, where there is currently compulsory generic substitution apart from a minority of situations [3, 4, 7, 8, 15, 19] ; -United Kingdom, where there is high voluntary INN prescribing encouraged through education and follow-up activities. This current averages over 82% across all products and up to 99.5% once drugs lose their patent, e.g. generic simvastatin [10, 15, 33, 37, 38] . Essential to increase the use of generics in Europe to maintain comprehensive health care?
Class Countries, measures and their influence with increasing prescribing efficiency
PPIs [6] [7] [8] [9] 15, 38, 104] Sweden versus Ireland:
• multiple demand side measures, including education, economics, and engineering, appreciably increased the prescribing of omeprazole in Sweden once generics became available, with stable and low utilisation of esomeprazole as a % of total PPI utilisation (<20% on a DDD basis) • this compared with Ireland with more limited demand side measures to combat industry activities, where utilisation of omeprazole decreased and the utilisation of esomeprazole increased following the availability of generic omeprazole, with both approximately 30% of total PPI utilisation in 2007 • this combined with the measures to lower the prices of generics in Sweden (Table I) . This compares with a 2.6 fold increase in expenditure in Ireland during the same period versus a 2.4 fold increase in utilisation • as a result, reimbursed expenditure (Euros/1000 inhabitants/year in Ireland (GMS populationgreater co-morbidity than the normal population) in 2007 was over 10 fold greater at over €60,000 versus €5832 for Sweden Netherlands:
• multiple demand side measures introduced in the Netherlands, coupled with supply side measures to lower generic prices (described in Table 1 ), led to reimbursed expenditure for the PPIs falling by 58% in 2010 vs. 2000. This was despite a 3 fold increase in utilisation Scotland:
• multiple demand side measures, coupled with supply-side measures to lower generic prices (Table I) , resulted in expenditure/1000 inhabitants/year for the PPIs in 2010 at GB£5481 (€6301), 56% below 2001 levels despite a 3 fold increase in utilisation • it is estimated that PPI expenditure in Scotland would have been GB£159mn per year greater in 2010 -assuming similar overall utilisation coupled with utilisation patterns and their costs kept the same as the pre-patent loss situation
Statins [6] [7] [8] [9] 38, 43, 104] Austria:
• restrictions limiting the prescribing of patented statins (atorvastatin and rosuvastatin), combined with measures to lower the prices of generics and originators (Table I) was over 10 fold greater than Sweden at over €60,000 versus €5192 for Sweden Netherlands:
• multiple demand side measures, coupled with supply side measures to lower generic prices (Table I) , led to reimbursed expenditure for the statins falling by 14% in 2010 vs. 2000 despite a 3.8 fold increase in utilisation Scotland:
• multiple demand side measures, coupled with supply-side measures to lower generic prices (Table I) , resulted in expenditure/1000 inhabitants/year for the statins in 2010 at GB£11420/1000 inhabitants (€13113) only 7% above 2001 levels despite a 6.2 fold increase in utilisation • expenditure for the statins would have been GB£290mn per year greater in 2010 assuming similar overall utilisation coupled with utilisation patterns and their costs kept the same as the pre-patent loss situation
ACEIs/ARBs [33, 44, 119] ACEIs and ARBs in Austria, Croatia and Scotland:
• expenditure (Euros)/1000 inhabitants/year remained relatively stable for the renin-angiotensin inhibitor drugs in Austria, Croatia and Scotland between 2001 and 2007 despite volumes increasing by between 69% to 159% during this period through multiple supply-side (see text) and demand side measures • multiple initiatives were undertaken in Scotland to limit ARB prescribing including education, economics and engineering initiatives Losartan versus other ARBs in Austria:
• the prescribing restrictions were relaxed for losartan, but not the other ARBs, following the availability of generic losartan • this appreciably increased the utilisation of losartan versus other single ARBs slowing down the rate of growth in ARB expenditure, with expenditure/DDD for losartan declining by 78% by the end of August 2011 compared with pre-patent loss prices Losartan versus other ARBs in NHS Bury:
• the Pharmacy team in NHS Bury instigated multiple measures to increase the prescribing of losartan versus other ARBs with generic losartan at appreciably lower prices than patented ARBs. These included educational activities, financial incentives as well as active switching programmes from other ARBs to losartan • the programmes led to estimated savings at over eight times the cost of implementation, helping to reach target expenditure goals without compromising care renin-angiotensin inhibitor system drugs. As discussed earlier, the products in each of these three classes or related classes are seen as essentially similar in all or nearly all patients. Consequently, the goal of health authorities and health insurance companies is to increase the prescribing of generics in each class once available, and restrict the utilisation of existing patented products. However, this is not easy with pharmaceutical companies investing considerable resources to influence the prescribing of particularly patented products, with promotional expenditure as high as US$53bn in the US alone in 2004 [31, [115] [116] [117] .
The ongoing reforms in Portugal described earlier also comprise multiple supply-and demand-side measures to considerably reduce pharmaceutical expenditure in light of the current financial situation [118] whilst still providing comprehensive health care.
DISCUSSION
We believe we have shown that health authorities and health insurance companies have successfully introduced a plethora of multiple supply-and demand-side measures and initiatives across Europe to appreciably improve prescribing efficiency. This is irrespective of the size of the population of the country. This includes measures to lower the price of generics as well as increase their utilisation versus originators and patented products in the class or related classes. Typically, multiple measures and initiatives are needed to appreciably change prescribing behaviour given the considerable resources spent by pharmaceutical companies on promotional activities and their known influence [120] [121] [122] [123] [124] [125] . Consequently, we believe these many reforms and initiatives are here to stay particularly in Europe given the current economic situation coupled with ageing populations, rising patient expectations and the continued launch of new premium priced drugs. As demonstrated (Table II) , the increasing use of generics at lower costs than patented drugs provides considerable opportunities for authorities to conserve resources without compromising care, especially if the quality of generics is maintained through the EMA and country regulatory authorities.
As a result, we believe it is inevitable that there will be increasing use of generics across Europe, especially as more standard drugs lose their patents. The alternative is insufficient funds to cover the costs of increasing drug volumes with ageing populations across Europe and/or difficulties with funding new [4, [6] [7] [8] [9] 15, 33, 37, 38, 50, 113, 114] . This is illustrated by the case histories in Table II for the PPIs, statins and the various targets linked with financial payments, the use of patient co-payments, financial incentives for physicians to adhere to formularies as well as prescribing restrictions for existing patented products in a class. However, the nature, timing and follow-up of any prescribing restrictions have to be carefully considered and addressed else health authorities and health insurance agencies could be disappointed with the outcome [9, 15, 33, 46, 112] . The pace of learning is likely to accelerate among European countries as resource pressures continue to grow, and will be the subject of future research.
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innovative drugs. Neither of these scenarios are in the best interests of key stakeholder groups including patients and physicians as well as innovative pharmaceutical companies. We are already seeing countries learning from each other (Tables I and II) . This includes initiatives to obtain low prices for generics through market forces and other measures. Examples include increasing the transparency in the prices of generics such as tendering and regular monitoring of the manufacturing costs as well as any discounts or rebates in the system. In addition, instigating advertising and other campaigns to allay potential patient fears regarding generics, compulsory INN prescribing or compulsory substitution. Examples of countries learning from each other regarding demand-side measures to increase the prescribing of generics versus patented products include prescribing
